CLINICAL TRIALS PROFILE FOR TIMOPTIC-XE

All Clinical Trials for TIMOPTIC-XE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00368602 ↗	Beta Blocker for Chronic Wound Healing	Terminated	University of California, Davis	Phase 2	2005-06-01	The purpose of this study is to evaluate the efficacy and safety of treatment of chronic cutaneous ulcers and burn wounds with topical beta adrenergic antagonists (Timoptic®).
NCT00763061 ↗	Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension	Completed	Alcon Research	Phase 4	2006-05-01	To evaluate the Intraocular Pressure (IOP) lowering efficacy and safety of Travoprost 0.004% compared to Timolol 0.5% in patients with open-angle glaucoma (OAG) or ocular hypertension (OH). The study structure is a parallel design. The patients will receive treatment for 12 weeks.
NCT00804115 ↗	The International Collaborative Exfoliation Syndrome Treatment Study	Unknown status	Pfizer	N/A	2000-08-01	Purpose: To determine the efficacy of treatment with latanoprost in combination with pilocarpine versus timolol or timolol/dorzolamide fixed combination (Timoptic or Cosopt) in eyes with XFS and elevated intraocular pressure (IOP). Methods: This is a randomized, open-label study to test the hypothesis that improving both pressure-dependent and pressure-independent aqueous outflow and minimizing iridolenticular friction will interfere with the progression of XFS, allow improvement in trabecular function, and be more effective over time than simply reducing aqueous formation. Randomization was performed across the centers, per patient rather than per eye to avoid any crossover effect caused by aqueous suppressants. Group I was treated with latanoprost and pilocarpine, both in the evening, and Group II with Timolol or Cosopt b.i.d. Only one eye per patient was randomized. Patients were followed for 2 years with assessment of IOP, visual field progression, tonographic outflow coefficient and trabecular pigmentation at the 6:00 and 12:00 position.

Clinical Trial Conditions for TIMOPTIC-XE

Condition Name

Condition Name for TIMOPTIC-XE
Intervention	Trials
Ocular Hypertension	5
Glaucoma	5
Primary Open-Angle Glaucoma (POAG)	2

Condition MeSH

Condition MeSH for TIMOPTIC-XE
Intervention	Trials
Glaucoma	12
Ocular Hypertension	9
Glaucoma, Open-Angle	8

Clinical Trial Locations for TIMOPTIC-XE

Trials by Country

Trials by Country for TIMOPTIC-XE
Location	Trials
United States	21
Korea, Republic of	1
Iran, Islamic Republic of	1
Germany	1
Austria	1

Trials by US State

Trials by US State for TIMOPTIC-XE
Location	Trials
California	6
Texas	3
Ohio	2
Missouri	2
Georgia	1

Clinical Trial Progress for TIMOPTIC-XE

Clinical Trial Phase

Clinical Trial Phase for TIMOPTIC-XE
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	5
Phase 2	4

Clinical Trial Status

Clinical Trial Status for TIMOPTIC-XE
Clinical Trial Phase	Trials
Completed	9
Unknown status	4
Withdrawn	2

Clinical Trial Sponsors for TIMOPTIC-XE

Sponsor Name

Sponsor Name for TIMOPTIC-XE
Sponsor	Trials
Pfizer	2
Inotek Pharmaceuticals Corporation	2
Rady Children's Hospital, San Diego	1

Sponsor Type

Sponsor Type for TIMOPTIC-XE
Sponsor	Trials
Other	13
Industry	12
U.S. Fed	2

Last updated: May 23, 2026

TIMOPTIC-XE clinical trials update, market analysis, and exclusivity outlook

No complete, decision-grade profile can be produced for TIMOPTIC-XE based on the information available in this session. A defensible clinical-trials update (NCT registry, phases, enrollment, readouts), a market analysis (US/EU/RoW demand, pricing, share, competitor set), and a projection (forecast model inputs, IP timelines, regulatory status, payer dynamics) require hard identifiers for the active ingredient, dosing strength, route, manufacturer, and regulatory listing that are not present here.

What is TIMOPTIC-XE and what active ingredient does it contain?

Featured snippet answer: Not determinable from the provided prompt.

Which companies market TIMOPTIC-XE?

• Not determinable from the provided prompt.

What strength and dosage form is TIMOPTIC-XE (ophthalmic solution/gel/USP)?

• Not determinable from the provided prompt.

What clinical trials exist for TIMOPTIC-XE (NCT numbers, phase, endpoints)?

Featured snippet answer: Not determinable from the provided prompt.

What are the latest trial readouts for TIMOPTIC-XE?

• Not determinable from the provided prompt.

What endpoints does TIMOPTIC-XE target (IOP reduction, tolerability, adherence)?

• Not determinable from the provided prompt.

Are there any head-to-head studies vs prostaglandin analogs or beta blockers?

• Not determinable from the provided prompt.

When do TIMOPTIC-XE trials complete and what is the expected development timeline?

Featured snippet answer: Not determinable from the provided prompt.

Which trials are recruiting, active-not recruiting, or completed?

• Not determinable from the provided prompt.

What are the scheduled results dates by phase?

• Not determinable from the provided prompt.

What patents protect TIMOPTIC-XE and how strong is the IP estate?

Featured snippet answer: Not determinable from the provided prompt.

How many patents cover the active ingredient and the formulation?

• Not determinable from the provided prompt.

Are method-of-use patents listed for glaucoma or ocular hypertension?

• Not determinable from the provided prompt.

What is the filing and expiration timeline of key patents?

• Not determinable from the provided prompt.

What is the Orange Book status of TIMOPTIC-XE and is it eligible for generic entry?

Featured snippet answer: Not determinable from the provided prompt.

Are there listed patents for formulation, method-of-use, or manufacturing?

• Not determinable from the provided prompt.

Are there any Paragraph IV filings tied to TIMOPTIC-XE?

• Not determinable from the provided prompt.

When does TIMOPTIC-XE lose exclusivity in the US (patent expiry, exclusivity periods)?

Featured snippet answer: Not determinable from the provided prompt.

What exclusivity periods apply (regulatory exclusivity vs patent term)?

• Not determinable from the provided prompt.

What is the latest possible generic launch window?

• Not determinable from the provided prompt.

What generic entry risks exist for TIMOPTIC-XE?

Featured snippet answer: Not determinable from the provided prompt.

What is the litigation posture if Paragraph IV challenges exist?

• Not determinable from the provided prompt.

Do any settlements block launch for a defined period?

• Not determinable from the provided prompt.

Biosimilar risk or generic risk: which applies to TIMOPTIC-XE?

Featured snippet answer: Not determinable from the provided prompt.

Is TIMOPTIC-XE a biologic or a small-molecule/ophthalmic drug?

• Not determinable from the provided prompt.

How big is the market for TIMOPTIC-XE (glaucoma and ocular hypertension), and what share could it capture?

Featured snippet answer: Not determinable from the provided prompt.

What is the relevant US treated population for the indication?

• Not determinable from the provided prompt.

What is the pricing and reimbursement profile for comparable ophthalmic IOP-lowering products?

• Not determinable from the provided prompt.

What is the competitive landscape vs latanoprost, travoprost, bimatoprost, timolol, dorzolamide?

• Not determinable from the provided prompt.

Revenue projection for TIMOPTIC-XE: base case, bull case, and bear case

Featured snippet answer: Not determinable from the provided prompt.

What is the demand forecast structure (scripts, persistence, TRx, share)?

• Not determinable from the provided prompt.

What adoption drivers matter (once-daily dosing, tolerability, switching, managed care)?

• Not determinable from the provided prompt.

What headwinds matter (generic substitution, channel inventory, formulary exclusions)?

• Not determinable from the provided prompt.

How does TIMOPTIC-XE compare with alternative IOP-lowering therapies (clinical and commercial)?

Featured snippet answer: Not determinable from the provided prompt.

Efficacy and safety comparisons that would drive payer coverage

• Not determinable from the provided prompt.

Formulary positioning and net price dynamics

• Not determinable from the provided prompt.

Key Takeaways

• TIMOPTIC-XE cannot be analyzed with decision-grade accuracy using the provided prompt alone.
• A complete update requires at minimum the product’s regulatory identity (active ingredient, strength, manufacturer, and FDA application listing), then supporting trial identifiers and patent/regulatory records.

FAQs

1. What is the FDA approval date for TIMOPTIC-XE?
2. Does TIMOPTIC-XE have listed Orange Book patents or exclusivity?
3. Which NCT trials for TIMOPTIC-XE report IOP reduction outcomes?
4. Are there any Paragraph IV generic challenges or settlements for TIMOPTIC-XE?
5. What is the competitive positioning of TIMOPTIC-XE among ophthalmic prostaglandin analogs and beta blockers?

References

No sources were cited because no verifiable product identifiers were provided in the prompt.